__timestamp | 1999 | 2002 | 2005 | 2016 |
---|---|---|---|---|
Friday, January 1, 1999 | 11.284022689285326 | |||
Tuesday, January 1, 2002 | 3.972943663529204 | |||
Saturday, January 1, 2005 | 111.61184036155946 | |||
Friday, January 1, 2016 | 966.7027036936738 |
Unleashing the power of data
Gilead Sciences, a leading biopharmaceutical company, has experienced significant fluctuations in its debt-to-equity ratio over the years. This ratio, a critical indicator of financial leverage, reveals how much debt the company uses to finance its assets relative to shareholders' equity.
It's important to note that data for some years is missing, which could provide a more comprehensive view of Gilead's financial journey. Nevertheless, the available data highlights significant shifts in the company's financial strategy over time.
Understanding these trends can offer valuable insights for investors and stakeholders, shedding light on Gilead's evolving approach to managing its financial health.
5 Year Trend in Average Market Capitalization for AbbVie
Annual Comparison of SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline
Average Market Capitalization of Abbvie Annually
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Comparison of Average SG&A Expense Ratio for AstraZeneca, Pfizer, and GlaxoSmithKline Over the Years
Number of Employees for Top 10 Pharma Companies
5 Year Trend in Average Market Capitalization for AbbVie
5 Year Trend in Market Capitalization for AbbVie
Comparison of R&D Expenses for Pfizer and AstraZeneca in 2023
Number of Employees for Top 10 Healthcare Companies
Comparison of Net Income Margin for Glaxosmithkline, AstraZeneca, Takeda, and Eli Lilly Over the Last 8 Quarters